Table 5.
Genetic alterations of MTOR in human cancers.
| Primary Tumor Tissues | Mutations (%) 1 | Copy Number Variations (%) 1 | Gene Expression (%) 1 | ||
|---|---|---|---|---|---|
| Gain | Loss | Over | Under | ||
| Adrenal gland | 0/658 (0%) | - | 4/267 (1.5%) | 1/79 (1.27%) | - |
| Autonomic ganglia | 0/1225 (0%) | - | - | - | - |
| Biliary tract | 51/1388 (3.67%) | - | - | - | - |
| Bone | 3/725 (0.41%) | - | - | - | - |
| Breast | 258/7666 (3.37%) | 1/1492 (0.07%) | 2/1492 (0.13%) | 39/1104 (3.53%) | 32/1104 (2.9%) |
| – ductal carcinoma | 120/2483 (4.83%) | - | - | - | - |
| – ER-positive carcinoma | 29/1363 (2.13%) | - | - | - | - |
| – HER-positive carcinoma | 8/205 (3.9%) | - | - | - | - |
| – basal (triple-negative) carcinoma | 5/372 (1.34%) | - | - | - | - |
| ER-PR-positive carcinoma | 6/308 (1.95%) | - | - | - | - |
| Central nervous system | 56/3499 (1.6%) | 1/1035 (0.1%) | - | 21/697 (3.01%) | 91/697 (13.06%) |
| Cervix | 21/388 (5.41%) | - | - | 18/307 (5.86%) | 5/307 (1.63%) |
| Endometrium | 103/988 (10.43%) | - | - | 27/602 (4.49%) | 9/602 (1.5%) |
| – endometrioid carcinoma | 82/649 (12.63%) | - | - | 23/545 (4.22%) | - |
| Eye | 3/179 (1.68%) | - | - | - | - |
| Hematopoietic and lymphoid | 118/6030 (1.96%) | - | - | 2/221 (0.9%) | 5/221 (2.26%) |
| Kidney | 165/2998 (5.5%) | - | - | 20/600 (3.33%) | 12/600 (2%) |
| Large intestine | 344/4526 (7.6%) | - | 1/718 (0.14%) | 16/610 (2.62%) | 35/610 (5.74%) |
| Liver | 175/2381 (7.35%) | - | - | 5/373 (1.34%) | - |
| Lung | 228/4930 (4.62%) | 3/1006 (0.3%) | 2/1006 (0.2%) | 44/1019 (4.32%) | 17/1019 (1.67%) |
| – adenocarcinoma | 126/2724 (4.63%) | 1/375 (0.27%) | 1/375 (0.27%) | 23/378 (6.08%) | 12/378 (3.17%) |
| – non-small cell carcinoma | 4/124 (3.23%) | - | - | - | - |
| – squamous cell carcinoma | 44/1004 (4.38%) | 1/500 (0.2%) | 1/500 (0.2%) | 11/502 (2.19%) | 5/502 (1%) |
| Meninges | 57/306 (18.63%) | - | - | - | - |
| Esophagus | 79/1673 (4.72%) | 1/510 (0.2%) | - | 5/125 (4%) | - |
| Ovary | 63/1396 (4.51%) | 1/684 (0.15%) | - | 26/266 (9.77%) | 11/266 (4.14%) |
| Pancreas | 83/2505 (3.31%) | - | - | 6/179 (3.35%) | 10/179 (5.59%) |
| Penis | 2/17 (11.76%) | - | - | - | - |
| Peritoneum | 1/43 (2.33%) | - | - | - | - |
| Pituitary | 0/89 (0%) | - | - | - | - |
| Pleura | 0/470 (0%) | - | - | - | - |
| Prostate | 217/3317 (6.54%) | - | 1/949 (0.11%) | 14/498 (2.81%) | - |
| Salivary gland | 7/410 (1.71%) | - | - | - | - |
| Skin | 236/2248 (10.5%) | 2/587 (0.34%) | - | 39/473 (8.25%) | 24/473 (5.07%) |
| Small intestine | 5/252 (1.98%) | - | - | - | - |
| Soft tissue | 18/1489 (1.21%) | - | - | - | - |
| Stomach | 124/1912 (6.49%) | 2/472 (0.42%) | - | 18/285 (6.32%) | 4/285 (1.4%) |
| Testis | 9/662 (1.36%) | - | - | - | - |
| Thymus | 0/173 (0%) | - | - | - | - |
| Thyroid | 42/2131 (1.97%) | - | - | 20/513 (3.9%) | 7/513 (1.36%) |
| Upper aerodigestive tract | 44/1836 (2.4%) | - | - | 26/522 (4.98%) | 5/522 (0.96%) |
| Urinary tract | 72/1209 (5.96%) | - | - | 34/408 (8.33%) | 2/408 (0.49%) |
| Vulva | 1/30 (3.33%) | - | - | - | - |
1 Mutated samples/total number of sample analyzed (%); -, no data. The data were derived from COSMIC v92 (released 27-AUG-20).